AGI-43192

• Description:

  AGI-43192 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that limitedly penetrates the blood-brain barrier. AGI-43192 exhibits inhibitory activitity against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC50s of 32 and 14 nM. AGI-43192 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-43192 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer[1].

• UNSPSC:

  12352005

• Target:

  Methionine Adenosyltransferase (MAT)

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/agi-43192.html

• Concentration:

  10mM

• Purity:

  99.47

• Solubility:

  DMSO : 13.89 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1C(C2=CC=C(Cl)C=C2)=C3N=C(NCC(F)(F)F)N=CC3=CN1C4=CC5=CN(C)N=C5C=C4

• Molecular Formula:

  C23H16ClF3N6O

• Molecular Weight:

  484.86

• References & Citations:

  [1] Li M, et al. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads. J Med Chem. 2022;65 (6) :4600-4615.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2377491-54-6]